Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469774) titled 'BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Biocity Biopharmaceutics Co., Ltd.
Condition:
Locally Advanced or Metastatic Solid Tumors
Intervention:
Drug: BC3195
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 17, 2026
Target Sample Size: 111
Countries of Recruitment:
China
To know more, visit https://clinicaltria...